1887

Abstract

is a sexually transmitted pathogen with increasing resistance to first- and second-line antimicrobials. The ‘near-patient test’ ResistancePlus MG FleXible (SpeeDx) detects plus four macrolide resistance mutations (MRMs), facilitating same-day patient follow up.

This assay has not been assessed on freshly collected samples.

Our goal was to evaluate the performance of the ResistancePlus MG FleXible test against the standard of care open platform test.

ResistancePlus MG FleXible (analysed on the Cepheid GeneXpert platform) was evaluated on freshly collected samples and compared to the standard of care open platform test ResistancePlus MG (SpeeDx) analysed on the LightCycler 480 II (Roche).

For 270 valid tests, ResistancePlus MG FleXible yielded a high positive per cent agreement (PPA) of 94.1% [96/102; 95 % confidence interval (CI): 87.6–97.8 %] and negative per cent agreement (NPA) of 95.2% (160/168; 95 % CI: 90.8–97.9%) for detection compared to the reference assay (kappa for test concordance of 0.89; 95 % CI: 0.83–0.95). Performance was similar across different sample types. For the detection of MRMs, ResistancePlus MG FleXible had a PPA of 97.1% (66/68; 95% CI: 89.8–99.6) and NPA of 78.6% (22/28; 95 % CI: 59.0–91.7), with test comparison kappa of 0.79 (95 % CI: 0.65–0.93). Notably, of six discordant results (i.e. determined to be wild type by the reference assay), five were positive for MRMs by Sanger sequencing, indicating that the ResistancePlus MG FleXible assay has an improved performance for mutation detection.

ResistancePlus MG FleXible had comparable test performance for detection as the open platform assay, with improved detection of MRMs. The ResistancePlus MG FleXible ‘near-patient’ assay can deliver a rapid result to expedite appropriate treatment.

Funding
This study was supported by the:
  • Suzanne M. Garland , Department of Health and Human Services, State Government of Victoria, http://dx.doi.org/10.13039/100012737, (Award VMRAF grant)
  • Catriona S. Bradshaw , Department of Health and Human Services, State Government of Victoria, http://dx.doi.org/10.13039/100012737, (Award VMRAF grant)
  • Gerald Murray , Department of Health and Human Services, State Government of Victoria, http://dx.doi.org/10.13039/100012737, (Award VMRAF grant)
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001271
2020-11-23
2021-03-01
Loading full text...

Full text loading...

/deliver/fulltext/jmm/70/1/jmm001271.html?itemId=/content/journal/jmm/10.1099/jmm.0.001271&mimeType=html&fmt=ahah

References

  1. Horner PJ, Martin DH. Mycoplasma genitalium infection in men. J Infect Dis 2017; 216:S396–S405 [CrossRef][PubMed]
    [Google Scholar]
  2. Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis 2015; 61:418–426 [CrossRef][PubMed]
    [Google Scholar]
  3. Machalek DA, Tao Y, Shilling H, Jensen JS, Unemo M et al. Prevalence of macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium: a systematic review and meta-analysis. Lancet Infect Dis 2020; 20:1302–1314 [CrossRef]
    [Google Scholar]
  4. Read TRH, Murray GL, Danielewski JA, Fairley CK, Doyle M et al. Symptoms, sites, and significance Mycoplasma genitalium in men who have sex with men. Emerg Infect Dis 2019; 25:719727 [CrossRef][PubMed]
    [Google Scholar]
  5. Durukan D, Read TRH, Murray G, Doyle M, Chow EPF et al. Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline-2.5g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability. Clin Infect Dis 2020; 71:1017–1024 [CrossRef][PubMed]
    [Google Scholar]
  6. Read TRH, Fairley CK, Murray GL, Jensen JS, Danielewski J et al. Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation. Clin Infect Dis 2019; 68:554–560 [CrossRef][PubMed]
    [Google Scholar]
  7. Sweeney EL, Mhango LP, Ebeyan S, Tan LY, Bletchly C et al. Evaluation of the ResistancePlus MG FleXible cartridge for near-point-of-care testing of Mycoplasma genitalium and associated macrolide resistance mutations. J Clin Microbiol 2020; 58:e01897–01819 [CrossRef][PubMed]
    [Google Scholar]
  8. Drud ST, Njuguna P, Ebeyan S, Erskine S, Holm M et al. Evaluation of the ResistancePlus MG flexible assay for detection of wild-type and 23S rRNA-Mutated Mycoplasma genitalium strains. J Clin Microbiol 2020; 58:e01900–01919 [CrossRef][PubMed]
    [Google Scholar]
  9. Twin J, Taylor N, Garland SM, Hocking JS, Walker J et al. Comparison of two Mycoplasma genitalium real-time PCR detection methodologies. J Clin Microbiol 2011; 49:1140–1142 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001271
Loading
/content/journal/jmm/10.1099/jmm.0.001271
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error